Tedatioxetine (大うつ病性障害)：医薬品市場予測及び分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Classification 14
3.3 Symptoms and Subtypes of Major Depressive Disorder 16
3.4 Prognosis 17
3.5 Quality of Life 17
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 19
4.1.3 Clinical Practice 22
5 Competitive Assessment 27
5.1 Overview 27
6 Unmet Needs and Opportunities 29
6.1 Overview 29
6.2 More Effective Pharmacotherapies 30
6.2.1 Unmet Needs 30
6.2.2 Gap Analysis 31
6.2.3 Opportunities 32
6.3 More Favorable Side Effect Profiles 32
6.3.1 Unmet Needs 32
6.3.2 Gap Analysis 33
6.3.3 Opportunities 33
6.4 Rapid Onset of Antidepressant Effects 34
6.4.1 Unmet Needs 34
6.4.2 Gap Analysis 34
6.4.3 Opportunities 34
6.5 Personalized Treatment Approach 35
6.5.1 Unmet Needs 35
6.5.2 Gap Analysis 36
6.5.3 Opportunities 36
7 Pipeline Assessment 37
7.1 Overview 37
7.2 Promising Drugs in Clinical Development 37
8 Tedatioxetine (Lu AA24530) 40
8.1 Overview 40
8.2 Efficacy 41
8.3 Safety 42
8.4 Dosing and Formulation 42
8.5 Potential Clinical and Commercial Positioning 42
8.6 SWOT Analysis 43
8.7 Forecast 43
9 Appendix 45
9.1 Bibliography 45
9.2 Abbreviations 48
9.3 Methodology 50
9.4 Forecasting Methodology 50
9.4.1 Diagnosed MDD Patients 50
9.4.2 Percent of Drug-Treated Patients 51
9.4.3 General Pricing Assumptions 51
9.4.4 Generic Erosion 52
9.4.5 Pricing of Pipeline Agents 52
9.5 Physicians and Specialists Included in this Study 53
9.6 About the Authors 55
9.6.1 Analyst 55
9.6.2 Therapy Area Directors 55
9.6.3 Global Head of Healthcare 56
9.7 About GlobalData 57
9.8 Disclaimer 57